GHENT, BELGIUM and OSLO, NORWAY--(Marketwire - Nov 21, 2012) - Ablynx (EURONEXT BRUSSELS: ABLX) and Algeta ASA (OSE: ALGETA) announce a research collaboration to evaluate a novel Targeted Thorium ...

OSLO, NORWAY--(Marketwired - Jun 11, 2013) - Algeta ASA (OSE: ALGETA) announces a collaboration with Australian biotechnology company Avipep Pty Ltd to evaluate a novel Targeted Thorium Conjugate (TTC ...

OSLO, August 28 /PRNewswire-FirstCall/ --Results Further Support the Clinical Profile of This Novel Anti-Cancer Agent Under Development to Improve the Survival of ...

- ALSYMPCA Study Designed to Evaluate Alpharadin for the Treatment ofBone Metastases in Prostate Cancer Patients Algeta ASA (OSE: ALGETA), the cancer therapeutics company, announces thatit is to ...

It’s going to cost an extra half-a-billion dollars, but German drug giant Bayer AG (BAYRY) said Thursday that has reached an agreement to acquire its Norwegian-based partner Algeta for $2.9 billion.

German pharmaceutical group Bayer offered to buy Norway's Algeta, its partner for a new prostate cancer treatment, for $2.4 billion, a 27 percent premium to the stock's last close, Algeta said on ...

OSLO/FRANKFURT (Reuters) - German drug firm Bayer (GER:BAYN) has clinched a $2.9 billion (1.7 billion pounds) deal to take over Norwegian cancer drug maker Algeta (OSL:ALGETA) after being tendered ...

Algeta ASA and Ablynx have announced a research collaboration to evaluate a novel Targeted Thorium Conjugate (TTC) based on combining Algeta’s proprietary thorium-227 alpha-pharmaceutical payload with ...

Oslo, Norway, 28 August 2013 - Algeta ASA (OSE: ALGETA), a company focused on the development of novel targeted cancer therapeutics, announces its results for the first half and second quarter 2013. A ...

Add Yahoo as a preferred source to see more of our stories on Google. BERLIN (AP) -- Germany's Bayer AG is set to acquire cancer drug maker Algeta ASA after raising its offer for the Norwegian-based ...

The Board of Directors of Algeta, the Norwegian cancer drugmaker, has confirmed that it has received a preliminary acquisition proposal from Bayer AG. The offer is said to be approximately $2.4 ...

Shares in Algeta, the Norwegian pharmaceutical company that specialises in cancer medicine, are up more than 30 per cent this morning after it confirmed in a statement to the Oslo stock exchange that ...